Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
Authors:
- 1 February 1992
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 66 (2) , 848-856
Abstract
Two monoclonal antibodies designated BAT085 and G3-136 were raised by immunizing BALB/c mice with gp120 purified from human immunodeficiency virus type 1 (HIV-1) IIIB-infected H9 cell extracts. Among three HIV-1 laboratory isolates (IIIB, MN, and RF), BAT085 neutralized only IIIB infection of CEM-SS cells, whereas G3-136 neutralized both IIIB and RF. These antibodies also neutralized a few primary HIV-1 isolates in the infection of activated human peripheral blood mononuclear cells. In indirect immunofluorescence assays, BAT085 bound to H9 cells infected with IIIB or MN, while G3-136 bound to H9 cells infected with IIIB or RF, but not MN. Using sequence-overlapping synthetic peptides of HIV-1 IIIB gp120, the binding site of BAT085 and G3-136 was mapped to a peptidic segment in the V2 region (amino acid residues 169 to 183). The binding of these antibodies to immobilized gp120 was not inhibited by the antibodies directed to the principal neutralization determinant in the V3 region or to the CD4-binding domain of gp120. In a competition enzyme-linked immunosorbent assay, soluble CD4 inhibited G3-136 but not BAT085 from binding to gp120. Deglycosylation of gp120 by endo-beta-N-acetylglucosaminidase H or reduction of gp120 by dithiothreitol diminished its reactivity with G3-136 but not with BAT085. These results indicate that the V2 region of gp120 contains multiple neutralization determinants recognized by antibodies in both a conformation-dependent and -independent manner.Keywords
This publication has 34 references indexed in Scilit:
- Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.Proceedings of the National Academy of Sciences, 1991
- High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.Proceedings of the National Academy of Sciences, 1990
- Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assayAIDS, 1990
- EFFECTS ON CD4 BINDING OF ANTIPEPTIDE SERA TO THE 4TH AND 5TH CONSERVED DOMAINS OF HIV-1 GP1201990
- Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected PersonsNew England Journal of Medicine, 1989
- An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1AIDS, 1989
- Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzeesVaccine, 1988
- Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.Proceedings of the National Academy of Sciences, 1988
- Neutralizing Antibodies and the Course of HIV-Induced DiseaseAIDS Research and Human Retroviruses, 1987
- Variable and conserved neutralization antigens of human immunodeficiency virusNature, 1986